Jpmorgan Chase & CO Candel Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CADL
# of Institutions
56Shares Held
6.41MCall Options Held
109KPut Options Held
130K-
Northpond Ventures, LLC1.94MShares$9.37 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA946KShares$4.58 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$3.98 Million0.0% of portfolio
-
State Street Corp Boston, MA492KShares$2.38 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA449KShares$2.17 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $140M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...